{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_050638.1:r.1441D>g",
          "cDNA Change": {
            "transcript": "NM_050638.1",
            "ref": "R",
            "alt": "G",
            "position": "1441"
          },
          "Protein Change": {
            "ref": "Arg",
            "alt": "Gly",
            "position": "529"
          },
          "Description in input context": "R1441G"
        },
        {
          "HGVS": "NM_050638.1:y.1700C>G",
          "cDNA Change": {
            "transcript": "NM_050638.1",
            "ref": "Y",
            "alt": "C",
            "position": "1700"
          },
          "Protein Change": {
            "ref": "Hypoxia-Inducible Factor 2",
            "alt": "Glutamic-to-Acetamido-Transferrin S-Specific Aspartic-α-Aminotransferase",
            "position": "1700"
          },
          "Description in input context": "Y1699C"
        },
        {
          "HGVS": "NM_050638.1:g.2019S",
          "cDNA Change": {
            "transcript": "NM_050638.1",
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Protein Change": {
            "ref": "Tyr",
            "alt": "Ser",
            "position": "2019"
          },
          "Description in input context": "G2019S"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0003958"
  },
  "Experiment Method": [
    {
      "Assay Method": "Affinity Purification followed by Mass Spectrometry",
      "Material used": {
        "Material Source": "Cell lines and patient-derived samples",
        "Material Name": "Human cells (HEK293, etc.)",
        "Description": "The study utilized human cell lines such as HEK293 for analysis."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_050638.1:r.1441D>g",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Disruption of the catalytic domain",
          "Result Description": "Phosphorylation at S937 was reduced by 20% in cells treated with R1441G."
        },
        {
          "Variant": "NM_050638.1:y.1700C>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Structural change leading to altered protein interaction",
          "Result Description": "In Y1699C, phosphorylation at S937 was decreased by 25%."
        },
        {
          "Variant": "NM_050638.1:g.2019S",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Disruption of the transmembrane domain",
          "Result Description": "G2019S resulted in a 30% reduction in phosphorylation at S937."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "The study included multiple biological replicates across different tissues."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Technical replicates were performed to ensure assay consistency."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "The presence of binding proteins (14-3-3) in untreated samples was confirmed."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Negative controls showed no significant phosphorylation at S937 under unstimulated conditions."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "2",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "1",
        "Counts": "1"
      },
      "Statistical analysis method": "Standard ANOVA followed by pairwise t-tests for multiple comparisons.",
      "Threshold for normal readout": {
        "Threshold for normal readout": "Phosphorylation at S937 ≥ 50% on day 7.",
        "Source": "Literature/Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Phosphorylation at S937 < 20% on day 7.",
        "Source": "Literature/Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes, commonly used in neurodegenerative disease studies."
      }
    }
  ]
}